Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00227318 · ClinicalTrials.gov registry record · Phase 3
TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial
A Phase 3 study of Hypertension, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT00227318 is a Phase 3 study of Hypertension that has completed, run by AstraZeneca. The registered enrollment target is 1,000 participants, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT00227318, a Phase 3 study of Hypertension, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the effectiveness of candesartan cilexetil in preventing hypertension in people with high normal blood pressure. Patients will be randomized to either Candesartan or placebo for an initial 2-year period followed by a second 2-year period of placebo for all patients.
Conditions Studied
Interventions
- DRUG ATACAND
Study Locations (20)
California
- Research Site - Long Beach
- Research Site - Redondo Beach
- Research Site - Santa Ana
- Research Site - Tustin
Florida
- Research Site - Bay Pines
- Research Site - Gainsville
- Research Site - Ocala
Missouri
- Research Site - Florissant
- Research Site - Kansas City
- Research Site - St Louis
Michigan
- Research Site - Chelsea
- Research Site - Detroit
Alabama
- Research Site - Mobile
Delaware
- Research Site - Wilmington
District of Columbia
- Research Site - Washington D.C.
Illinois
- Research Site - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 1998-07 |
| Est. Completion | 2005-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00227318
The ClinicalTrials.gov registry entry for NCT00227318 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (71% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which ATACAND is the first listed.
NCT00227318 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT00227318 about?
NCT00227318 is a clinical study titled "TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial". The purpose of this study is to determine the effectiveness of candesartan cilexetil in preventing hypertension in people with high normal blood pressure. Patients will be randomized to either Candesartan or placebo for an initial 2-year period followed by a second 2-year period of placebo for all p...
What is the current status of trial NCT00227318?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 1998-07. Estimated completion is 2005-10.
What conditions does trial NCT00227318 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00227318?
The interventions under investigation include: ATACAND (DRUG).
Who is sponsoring clinical trial NCT00227318?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00227318 being conducted?
This trial has 20 study locations across Alabama, California, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.